Rafael Holdings Inc Dossier
Qualitative Analysis
Business overview
Rafael Holdings, Inc. (NYSE: RFL) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for rare diseases and cancer. The company's lead clinical program is Trappsol® Cyclo™ (hydroxypropyl beta cyclodextrin), an investigational drug being evaluated for the treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, progressive, and fatal genetic disorder. Rafael Holdings operates primarily through its Healthcare segment, which includes its wholly-owned subsidiary Cyclo Therapeutics, LLC (acquired in March 2025), alongside majority interests in LipoMedix Pharmaceuticals, Cornerstone Pharmaceuticals, and Rafael Medical Devices. The company also holds a legacy commercial real estate asset in Jerusalem, Israel.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Focusing resources primarily on the clinical development, regulatory approval, and commercialization of lead candidate Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1).
Expected impact: Establishment of a commercial-stage rare disease and oncology platform.
Securing exclusive intellectual property rights to target ApoE4-positive Alzheimer's Disease patients using cyclodextrins.
Expected impact: Broadens the therapeutic utility of Trappsol® Cyclo™ into a high-prevalence subgroup of Alzheimer's Disease (50-70% of AD cases).
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To combine resources and focus on the development and commercialization of Trappsol® Cyclo™ for Niemann-Pick Disease Type C1, establishing it as Rafael's lead clinical program.
Financial impact: Created $30.0 million in in-process R&D (IPR&D) and $19.9 million in goodwill, significantly increasing consolidated R&D expenses.
Strategic Partnerships
Provides exclusive rights to U.S. Patent No. 12285440, covering the use of cyclodextrins in Alzheimer's Disease patients carrying the ApoE4 genetic mutation.
Terms: Terms of the licensing agreement were not publicly disclosed.